Elinzanetant (CHEM136187)
| Record Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Version | 1.0 | ||||||||
| Creation Date | 2026-04-15 16:21:40 UTC | ||||||||
| Update Date | 2026-08-22 11:08:24 UTC | ||||||||
| Accession Number | CHEM136187 | ||||||||
| Identification | |||||||||
| Common Name | Elinzanetant | ||||||||
| Class | Small Molecule | ||||||||
| Description | Elinzanetant is an organoheterocyclic compound with the formula C33H35F7N4O3. Elinzanetant belongs to the piperazines, a subclass of diazinanes within the organic compounds. With an average molecular weight of 668.66 g/mol, Elinzanetant is a heavy molecule. Regarding its pharmacological profile, this compound acts as an antagonist of two protein targets: the Substance-P receptor (TACR1) and the Neuromedin-K receptor (TACR3). | ||||||||
| Contaminant Sources | Not Available | ||||||||
| Contaminant Type | Not Available | ||||||||
| Chemical Structure |  | ||||||||
| Synonyms | Not Available | ||||||||
| Chemical Formula | C33H35F7N4O3 | ||||||||
| Average Molecular Mass | 668.657 g/mol | ||||||||
| Monoisotopic Mass | 668.260 g/mol | ||||||||
| CAS Registry Number | 929046-33-3 | ||||||||
| IUPAC Name | N-[6-[(7S,9aS)-7-(hydroxymethyl)-3,4,6,7,9,9a-hexahydro-1H-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)-3-pyridinyl]-2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamide | ||||||||
| Traditional Name | Not Available | ||||||||
| SMILES | [H][C@]12COCCN1C[C@@H](CO)N(C2)C1=CC(=C(C=N1)N(C)C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CC=C(F)C=C1C | ||||||||
| InChI Identifier | InChI=1S/C33H35F7N4O3/c1-19-9-23(34)5-6-26(19)27-13-29(44-16-25-18-47-8-7-43(25)15-24(44)17-45)41-14-28(27)42(4)30(46)31(2,3)20-10-21(32(35,36)37)12-22(11-20)33(38,39)40/h5-6,9-14,24-25,45H,7-8,15-18H2,1-4H3/t24-,25-/m0/s1 | ||||||||
| InChI Key | DWRIJNIPBUFCQS-DQEYMECFSA-N | ||||||||
| Chemical Taxonomy | |||||||||
| Classification | Not classified | ||||||||
| Biological Properties | |||||||||
| Status | Detected and Not Quantified | ||||||||
| Origin | Not Available | ||||||||
| Cellular Locations | Not Available | ||||||||
| Biofluid Locations | Not Available | ||||||||
| Tissue Locations | Not Available | ||||||||
| Pathways | Not Available | ||||||||
| Applications | Not Available | ||||||||
| Biological Roles | Not Available | ||||||||
| Chemical Roles | Not Available | ||||||||
| Physical Properties | |||||||||
| State | Not Available | ||||||||
| Appearance | Not Available | ||||||||
| Experimental Properties |
| ||||||||
| Predicted Properties | Not Available | ||||||||
| Spectra | |||||||||
| Spectra |
| ||||||||
| Toxicity Profile | |||||||||
| Route of Exposure | Not Available | ||||||||
| Mechanism of Toxicity | Not Available | ||||||||
| Metabolism | Not Available | ||||||||
| Toxicity Values | Not Available | ||||||||
| Lethal Dose | Not Available | ||||||||
| Carcinogenicity (IARC Classification) | Not Available | ||||||||
| Uses/Sources | Not Available | ||||||||
| Minimum Risk Level | Not Available | ||||||||
| Health Effects | Not Available | ||||||||
| Symptoms | Not Available | ||||||||
| Treatment | Not Available | ||||||||
| Concentrations | |||||||||
| Not Available | |||||||||
| External Links | |||||||||
| Identifiers | Not Available | ||||||||
| References | |||||||||
| Synthesis Reference | Not Available | ||||||||
| MSDS | Not Available | ||||||||
| General References | Not Available | ||||||||
